Gazelle Parent, Inc. filed the registration statement on April 22, 2026. Galera has agreed to sell Series C preferred stock for about $350.0 million, less certain Obsidian financing proceeds, before the mergers close.
Latest Obsidian Therapeutics news
We have not published a story on Obsidian Therapeutics yet. When there is news, it will appear here.
Questions about Obsidian Therapeutics
Is Obsidian Therapeutics involved in a merger or acquisition?
Our latest story on this, dated Apr 22, 2026: "Galera and Obsidian Therapeutics merger moves forward with Gazelle Parent S-4". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Obsidian Therapeutics?
Obsidian Therapeutics, Inc. trades under the ticker OBX on NASDAQ.
Where is Obsidian Therapeutics listed?
Obsidian Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Obsidian Therapeutics?
The SEC Central Index Key (CIK) for Obsidian Therapeutics, Inc. is 2130606. Its filings are on SEC EDGAR.
How many shares does Obsidian Therapeutics have outstanding?
61,772,876 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Which country or territory is Obsidian Therapeutics listed under?
Our directory records Obsidian Therapeutics, Inc. under United States.
What does Obsidian Therapeutics do?
Our directory classifies Obsidian Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Obsidian Therapeutics?
The ISIN recorded for Obsidian Therapeutics, Inc. is US67448A1060.
Does aibio.space cover Obsidian Therapeutics?
aibio.space lists Obsidian Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What is the latest Obsidian Therapeutics (OBX) stock news?
Our latest story on Obsidian Therapeutics, dated Apr 22, 2026: "Galera and Obsidian Therapeutics merger moves forward with Gazelle Parent S-4". Gazelle Parent, Inc. filed the registration statement on April 22, 2026. Galera has agreed to sell Series C preferred stock for about $350.0 million, less certain Obsidian financing proceeds, before the mergers close. Source.
How long will Obsidian Therapeutics's cash last?
From our story of Apr 22, 2026: It says existing cash plus net proceeds of the mergers and concurrent financing will fund operations into the third quarter of 2026. Source.
How much cash does Obsidian Therapeutics have?
From our story of Apr 22, 2026: One risk factor reports $80.5 million of cash, cash equivalents and marketable securities as of December 31, 2025. Source.
Is Obsidian Therapeutics a smaller reporting company?
SEC records list Obsidian Therapeutics, Inc.'s filer category as: Non-accelerated filer<br>Emerging growth company.
Where is Obsidian Therapeutics headquartered?
SEC records list its business address as 1030 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02138.
When does Obsidian Therapeutics's fiscal year end?
Obsidian Therapeutics, Inc.'s fiscal year ends on December 31, per SEC records.
Investor discussion: Obsidian Therapeutics
Members talk about Obsidian Therapeutics (OBX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Obsidian Therapeutics, newest first. Each line links the filing it comes from.
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Legal
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.01,2.02,3.02,3.03,4.01,5.01,5.02,5.03,7.01,9.01). Source
Mergers
Filed documents for a merger or acquisition. SEC Form S-4. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:OBX on TradingView.
SEC filings and registration
SEC name
Obsidian Therapeutics, Inc.
CIK
2130606
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
OBX (Nasdaq)
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Emerging growth company
Business address
1030 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02138
Phone
(781) 806-6245
Shares outstanding
61,772,876 as of 2026-08-10 (10-Q filed 2026-08-14)
Former names
Gazelle Parent, Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Obsidian Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker OBX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio